Synaptogenix Inc (SNPX)

[Cyosol]

I think the partnerships with academic institutions are just for the trial design. When it comes to actually conducting the trials, they'll have to go back to WCT and pay another $12 million or so.

Now if they only raise another $20 million like in 2016 rather than the full $100 million shelf offering, that should only dilute us by another 2-3 million shares or so.

In that case, we would have about 16-17 million shares after dilution when results are announced next year.

Positive results could then significantly lift the stock price and let them raise the other $80 million for a better price in 2019/2020.